Asia Pacific Cell and Gene Therapy Manufacturing Services Market Forecast to 2030

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Forecast to 2030

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 – Regional Analysis – by Type [Cell Therapy (Autologous and Allogenic) and Gene Therapy (Viral and Non-Viral Vector)], Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User [Pharmaceutical and Biotechnology Companies and Contract Research Organization (CROs)]

Send Enquiry
Item ID: BMIRE00029300 Category: Tag:

$2,485 – $3,885

Description

The Asia Pacific cell and gene therapy manufacturing services market is expected to grow from US$ 1,007.42 million in 2022 to US$ 3,613.18 million by 2030. It is estimated to grow at a CAGR of 17.3% from 2022 to 2030.

Automation of Cell and Gene Therapy Manufacturing Services Drives Asia Pacific Cell and Gene Therapy Manufacturing Services Market

Incorporating automation in cell and gene therapy manufacturing would lead to a reduced risk of contamination, improved consistency, and decreased cost of production. Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are a few of the devices available in the market to enable automation. These products have been designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. The rising demand for cell and gene therapies has shifted the production of cell and gene therapy products from a small-volume process to a large-volume process worldwide. In addition to the increasing research activities, the evolution of cell and gene therapy from an academic and clinical setting to mass production and commercialization has propelled the demand for automation in commercial manufacturing. In July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the capability of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software), along with reagents, consumables, and instruments. Thus, automation is emerging as a new trend in the Asia Pacific cell and gene therapy manufacturing services market.

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Overview

Asia Pacific region comprises of China, Japan, India, Australia, South Korea, and Rest of Asia Pacific countries. The Asia Pacific region is one of the leading regions in the field of cell and gene therapy, with several countries which are involved in the investing in research and development of these therapies. Japan is one of the leaders in the Asia Pacific region when it comes to cell and gene therapies. In 2014, Japan was the first country to approve a cell therapy product, a treatment for macular degeneration. Several other cell and gene therapies have been approved in the country since then, including the CAR-T for leukemia and lymphoma.

China is the first country to approve a gene therapy in 2003, since then cell and gene therapy development has advanced rapidly worldwide, and their therapeutic potential has soared. China’s government has conducted several regulatory reforms to promote normative development of cell and gene therapies. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials across the world. Currently, China has nearly 400 ongoing CAR-T trials centered on hematology and oncology and solid tumors. Cell therapy in China is entering a new era with the approval of Fosun Kite’s Yescarta and JW Therapeutics’ Relma-cel in 2021 from the National Medical Products Administration (NMPA). Due to lower costs and larger patient populations, several multinational companies have moved to the region to take advantage of these factors.

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation

The Asia Pacific cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.

Based on type, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the Asia Pacific cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the Asia Pacific cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on application, the Asia Pacific cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on end user, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on country, the Asia Pacific cell and gene therapy manufacturing services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2022, China registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd are some of the leading companies operating in the Asia Pacific cell and gene therapy manufacturing services market.

Summary Info

Industry:

Pricing options:

, ,

Publishing status:

Geographical coverage:

, ,

Year of Publication:

At 17.3% CAGR, the Asia Pacific Cell and Gene Therapy Manufacturing Services Market is Speculated to be worth US$ 3,613.18 million by 2030, says the research team

According to the research team’ research, the Asia Pacific cell and gene therapy manufacturing services market was valued at US$ 1,007.42 million in 2022 and is expected to reach US$ 3,613.18 million by 2030, registering a CAGR of 17.3% from 2022 to 2030. Strategic initiatives by companies and automation of cell and gene therapy manufacturing services are among the critical factors attributed to the Asia Pacific cell and gene therapy manufacturing services market expansion.

Companies operating in the Asia Pacific cell and gene therapy manufacturing services market focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few of the noteworthy developments in the cell and gene therapy manufacturing services market are mentioned below.

• In May 2023, Lonza launched the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation devised to optimize and streamline CAR T-cell manufacturing. The TheraPEAK T-VIVO Cell Culture Medium can exhibit a high performance without the need to add human serum or its components, unlike other serum-free media.

• In October 2022, Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.

• In March 2022, Cellevolve Bio partnered with Seattle Children’s Therapeutics to develop and commercialize new multiplex CARs for paediatric cancers. Under the collaboration, the partners will focus on the BrainChild research program, a suite of five multiplex CARs, to treat pediatric central nervous system (CNS) malignancies. In partnership, they would leverage the Seattle Children’s Cure Factory facility to conduct early clinical GMP research on new CARs.

• In March 2022, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Upon collaboration, the companies had plans of combining Twist’s antibody libraries with Kriya’s proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya’s gene therapy technology.

Thus, these strategic initiatives create significant growth opportunities in the Asia Pacific cell and gene therapy manufacturing services market.

On the contrary, high cost of cell and gene therapy manufacturing hurdles the growth of Asia Pacific cell and gene therapy manufacturing services market.

Based on type, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. The cell therapy segment held 68.3% share of Asia Pacific cell and gene therapy manufacturing services market in 2022, amassing US$ 687.78 million. It is projected to garner US$ 2,498.47 million by 2030 to expand at 17.5% CAGR during 2022-2030. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the Asia Pacific cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. The cancer segment held 56.3% share of Asia Pacific cell and gene therapy manufacturing services market in 2022, amassing US$ 566.93 million. It is projected to garner US$ 2,164.42 million by 2030 to expand at 18.2% CAGR during 2022-2030.

Based on application, the Asia Pacific cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. The commercial manufacturing segment held 63.1% share of Asia Pacific cell and gene therapy manufacturing services market in 2022, amassing US$ 636.16 million. It is projected to garner US$ 2,404.04 million by 2030 to expand at 18.1% CAGR during 2022-2030.

Based on end user, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). The pharmaceutical and biotechnology companies segment held 78.3% share of Asia Pacific cell and gene therapy manufacturing services market in 2022, amassing US$ 788.69 million. It is projected to garner US$ 2,850.25 million by 2030 to expand at 17.4% CAGR during 2022-2030.

Based on country, the Asia Pacific cell and gene therapy manufacturing services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 35.3% share of Asia Pacific cell and gene therapy manufacturing services market in 2022. It was assessed at US$ 355.32 million in 2022 and is likely to hit US$ 1,338.17 million by 2030, exhibiting a CAGR of 18.0% during 2022-2030.

Key players operating in the Asia Pacific cell and gene therapy manufacturing services market are Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co LtdĀ, among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific cell and gene therapy manufacturing services market.
o Highlights key in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cell and gene therapy manufacturing services market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the cell and gene therapy manufacturing services market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Increase in Number of Approval of Cell and Gene Therapies
4.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
4.2 Market Restraints
4.2.1 High Cost of Cell and Gene Therapy Manufacturing
4.3 Market Opportunities
4.3.1 Strategic Initiatives by Companies
4.4 Future Trends
4.4.1 Automation of Cell and Gene Therapy Manufacturing Services
4.5 Impact Analysis:
5. Cell and Gene Therapy Manufacturing Services Market – Asia Pacific Market Analysis
5.1 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 – 2030
6. Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Cell Therapy
6.3.1 Overview
6.3.2 Cell Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Autologous
6.3.2.1.1 Overview
6.3.2.1.2 Autologous: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.2 Allogenic
6.3.2.2.1 Overview
6.3.2.2.2 Allogenic: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Gene Therapy
6.4.1 Overview
6.4.2 Gene Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Viral Vector
6.4.2.1.1 Overview
6.4.2.1.2 Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.4.2.2 Non-Viral Vector
6.4.2.2.1 Overview
6.4.2.2.2 Non-Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 – by Indication
7.1 Overview
7.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Orthopedics
7.4.1 Overview
7.4.2 Orthopedics: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
8.4 Clinical Manufacturing
8.4.1 Overview
8.4.2 Clinical Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Commercial Manufacturing
8.5.1 Overview
8.5.2 Commercial Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
9.4 Pharmaceutical and Biotechnology Companies
9.4.1 Overview
9.4.2 Pharmaceutical & Biotechnology Companies: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Contract Research Organizations (CROs)
9.5.1 Overview
9.5.2 Contract Research Organizations (CROs): Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – Country Analysis
10.1 Overview
10.1.1 Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
10.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.1.1.2 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.1.2 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.1.3 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.1.4 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
10.1.1.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.2.1.1 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.2.1.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.2.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.2.3 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.2.4 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
10.1.1.3 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.3.1.1 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.3.1.2 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.3.2 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.3.3 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.3.4 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
10.1.1.4 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.4.1.1 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.4.1.2 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.4.2 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.4.3 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.4.4 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
10.1.1.5 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.5.1.1 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.5.1.2 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.5.2 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.5.3 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.5.4 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
10.1.1.6 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.6.1.1 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.6.1.2 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
11. Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Thermo Fisher Scientific Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Merck KGaA
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Charles River Laboratories International Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Lonza Group AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 WuXi AppTec Co Ltd?
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Catalent Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Takara Bio Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Nikon Corp
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 FUJIFILM Holdings Corp
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments

LIST OF TABLES

Table 1. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation
Table 2. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 3. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 4. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 5. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 6. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 7. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 8. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 9. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 10. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 11. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million
Table 12. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 13. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 14. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 15. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 16. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 17. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 18. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 19. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 20. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 21. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 22. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 23. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 24. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 25. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 26. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 27. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 28. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 29. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 30. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 31. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 32. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 33. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 34. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 35. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 36. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 37. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 38. Recent Organic Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market
Table 39. Recent Inorganic Growth Strategies in the Asia Pacific Cell and Gene Therapy Manufacturing Services Market

LIST OF FIGURES

Figure 1. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation, By Country
Figure 2. Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
Figure 6. Cell Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Autologous: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Allogenic: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Gene Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Non-Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
Figure 13. Cancer: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Orthopedics: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
Figure 17. Clinical Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Commercial Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
Figure 20. Pharmaceutical & Biotechnology Companies: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Contract Research Organizations (CROs): Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Asia Pacific: Cell and Gene Therapy Manufacturing Services Market, by Key Region – Revenue (2022) (US$ Million)
Figure 23. Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
Figure 24. China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market

The List of Companies – Asia Pacific Cell and Gene Therapy Manufacturing Services Market

1. Catalent Inc
2. Charles River Laboratories International Inc
3. FUJIFILM Holdings Corp
4. Lonza Group AG
5. Merck KgaA
6. Nikon Corp
7. Takara Bio Inc
8. Thermo Fisher Scientific Inc
9. WuXi AppTec Co Ltd

Reviews

There are no reviews yet.

Be the first to review “Asia Pacific Cell and Gene Therapy Manufacturing Services Market Forecast to 2030”